The 20th World Congress of the World Society of Cardio Thoracic Surgeons, held in Chennai on 24th October 2010, brought together some of the world leading cardiac surgeons and specialists to share insights on advanced heart treatment strategies. This prestigious global gathering served as an important platform for discussing both surgical and non surgical innovations in cardiac care.
During the congress, Vaso Meditech Pvt Ltd actively participated and connected with cardio thoracic experts from across the globe. Known in India for its contribution to EECP and SphygmoCor technologies, the company presence attracted significant attention. Many specialists showed keen interest in emerging methods to improve outcomes for high risk cardiac patients.
One of the key highlights was the presentation of a clinical approach involving enhanced external counter pulsation therapy prior to high risk Coronary Artery Bypass Grafting CABG. This strategy explored how EECP therapy could support patients before surgery by improving blood circulation and potentially reducing the need for intra aortic balloon pump support IABP.
Enhanced External Counter Pulsation EECP is widely recognized as a non invasive therapy that enhances blood flow to the heart and encourages the development of collateral circulation, often described as a natural bypass around blocked arteries. For patients with coronary artery disease, especially those at higher surgical risk, it is increasingly considered a valuable option in treatment of heart blockage without surgery.
The protocol presented at the congress highlighted how EECP is being integrated into pre surgical cardiac care. It demonstrated that the therapy can play a supportive role alongside surgery by helping stabilize patients and improving their readiness for procedures such as bypass surgery.
Participation in this international congress further reinforced the global recognition of enhanced external counter pulsation therapy. The discussions in Chennai reflected a broader shift toward combining non invasive therapies with surgical cardiac care to improve patient safety and achieve better long term heart health outcomes.
EECP THERAPY uses a proprietary technology to inflate and deflate a series of pneumatic cuffs enclosing the lower extremities of the patients. Treatment is administered on a padded table in which three sets of electronically controlled inflation and deflation valves are located.
